Lajos Pusztai
拉约什·普斯泰
MD, DPhil
Professor of Medicine, Director of Breast Cancer Translational Research医学教授，乳腺癌转化研究主任
👥Biography 个人简介
Lajos Pusztai is a leading TNBC researcher at Yale, known for integrating genomics into neoadjuvant immunotherapy trials. He has pioneered biomarker-driven approaches to predict immunotherapy response in triple-negative breast cancer and shaped treatment paradigms globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Neoadjuvant Immunotherapy in TNBC
Led key trials combining checkpoint inhibitors with chemotherapy in early TNBC, establishing pathological complete response as a surrogate endpoint for survival.
Genomic Biomarker Discovery
Developed genomic classifiers to predict chemotherapy and immunotherapy sensitivity, enabling personalized neoadjuvant regimen selection in breast cancer.
Representative Works 代表性著作
Pembrolizumab plus chemotherapy in early-stage TNBC (KEYNOTE-522)
New England Journal of Medicine (2022)
Landmark trial demonstrating pembrolizumab + chemotherapy improved pCR and EFS in early TNBC, supporting FDA approval.
Tumor mutational burden and immune gene expression predict immunotherapy benefit in TNBC
Journal of Clinical Oncology (2021)
Identified genomic predictors of immunotherapy response, advancing precision medicine in TNBC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sara Tolaney
Dana-Farber Cancer Institute
Sylvia Adams
NYU Langone Health / Perlmutter Cancer Center
Aditya Bardia
UCLA Jonsson Comprehensive Cancer Center
Erica Mayer
Dana-Farber Cancer Institute
关注 拉约什·普斯泰 的研究动态
Follow Lajos Pusztai's research updates
留下邮箱，当我们发布与 Lajos Pusztai（Yale School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment